Jubilant Ingrevia Limited, a global integrated Life Science products and Innovative Solutions provider, today announced the commissioning of its new Diketene derivatives facility at its manufacturing site in Gajraula.

The newly commissioned facility marks the entry of Jubilant Ingrevia Limited into the fast growing Diketene business portfolio. This reiterates Jubilant Ingrevia’s commitment towards growth through its integrated business model, by providing value added products and innovative solutions to its customers.

The commissioned facility has about 7,000 TPA capacity to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate). The company’s long-standing association with leading customers in pharmaceuticals, agrochemicals and other industries and its advance efforts to get product approval from customers, will help in utilizing a major portion of the capacity of this new facility in the coming months. Jubilant Ingrevia Limited undertakes to commission future phases of Diketene Derivatives as per plan.

Rajesh Srivastava, Chief Executive Officer & Managing Director, Jubilant Ingrevia Limited said, “It gives me immense pleasure to showcase yet another instance where Jubilant Ingrevia Limited has developed a strong chemistry platform proposition using inhouse R&D and technology transfer backed with high operating excellence and clear strategic direction. The commercial launch of the Diketene facility marks the next stage in the growth of the company, positioning us closer to our client’s requirements of innovative products and solutions using novel and niche chemistry platforms."